Skip to main content
Top
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Psychotherapy | Research article

Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder

Authors: Albert Yi-Que Truong, Brian Fabian Saway, Malek H. Bouzaher, Mustafa Nawroz Rasheed, Sanaz Monjazeb, Soleille Dorothy Everest, Susan Linda Giampalmo, David Hartman, Cheryl Hartman, Anita S. Kablinger, Robert L. Trestman

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Background

Clinical trials provide consistent evidence for buprenorphine’s efficacy in treating opioid use disorder (OUD). While the Drug Addiction Treatment Act of 2000 requires physicians to combine medication-assisted treatment (MAT) with behavioral intervention, there is no clear evidence for what form or elements of psychotherapy are most effective when coupled with MAT to treat OUD. This investigation involves focus groups designed to collect patient opinions about a specific psychotherapy, called START NOW, as well as general beliefs about various elements of psychotherapy for treating OUD. Our analysis reveals trends about patient preferences and strategies for improving OUD treatment.

Methods

Subjects included patients enrolled in buprenorphine/naloxone MAT at our institution’s office-based opioid treatment program. All subjects participated in a single START NOW group session, which was led by a provider (physician or nurse practitioner trained and standardized in delivering START NOW). Consented subjects participated in satisfaction surveys and audio-recorded focus groups assessing individual beliefs about various elements of psychotherapy for treating OUD.

Results

Overall, 38 different focus groups, 92 participation events, and 44 unique subjects participated in 1-to-6 different START NOW session/audio-recorded focus group sessions led by a certified moderator. Demographic data from 36/44 subjects was collected. Seventy-five percent (33/44) completed the START NOW Assessment Protocol, which revealed self-reported behavioral trends. Analysis of all 92 START NOW Satisfaction Questionnaire results suggests that subjects’ opinions about START NOW improved with increased participation. Our analysis of audio-recorded focus groups is divided into three subsections: content strategies for new psychotherapies, implementation strategies, and other observations. For example, participants request psychotherapies to target impulsivity and to teach future planning and build positive relationships.

Conclusions

The results of this study may guide implementation of psychotherapy and improve the treatment of OUD, especially as it relates to improving the modified START NOW program for treating OUD. Our study also reveals a favorable outlook of START NOW with increased participation, suggesting that any initial reticence to this program can be overcome to allow for effective implementation.
Appendix
Available only for authorised users
Literature
4.
go back to reference North CS, Eyrich KM, Pollio DE, Spitznagel EL. Are rates of psychiatric disorders in the homeless population changing? Am J Public Health. 2004;94(1):103–8.PubMedPubMedCentralCrossRef North CS, Eyrich KM, Pollio DE, Spitznagel EL. Are rates of psychiatric disorders in the homeless population changing? Am J Public Health. 2004;94(1):103–8.PubMedPubMedCentralCrossRef
5.
go back to reference Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38(11):2724–8.PubMedCrossRef Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38(11):2724–8.PubMedCrossRef
6.
go back to reference Fareed A, Eilender P, Ketchen B, Buchanan-Cummings AM, Scheinberg K, Crampton K, Nash A, Shongo-Hiango H, Drexler K. Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med. 2014;8(5):345–50.PubMedCrossRef Fareed A, Eilender P, Ketchen B, Buchanan-Cummings AM, Scheinberg K, Crampton K, Nash A, Shongo-Hiango H, Drexler K. Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med. 2014;8(5):345–50.PubMedCrossRef
8.
go back to reference Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on alcohol and related conditions. Psychol Med. 2012;42(6):1261–72.PubMedCrossRef Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on alcohol and related conditions. Psychol Med. 2012;42(6):1261–72.PubMedCrossRef
9.
go back to reference Brooner RK, King VL, Kidorf M. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71–80.PubMedCrossRef Brooner RK, King VL, Kidorf M. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71–80.PubMedCrossRef
10.
go back to reference Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict. 2013;22(3):261–5.PubMedPubMedCentralCrossRef Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict. 2013;22(3):261–5.PubMedPubMedCentralCrossRef
11.
go back to reference Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.PubMedPubMedCentralCrossRef Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.PubMedPubMedCentralCrossRef
12.
go back to reference Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors for opioid abuse and illicit drug use in chronic pain patients. J Opioid Management. 2007;3(2):89–100.CrossRef Manchikanti L, Giordano J, Boswell MV, Fellows B, Manchukonda R, Pampati V. Psychological factors as predictors for opioid abuse and illicit drug use in chronic pain patients. J Opioid Management. 2007;3(2):89–100.CrossRef
13.
go back to reference Hooker SA, Sherman MD, Lonergan-Cullum M, Sattler A, Liese BS, Justesen K, Nissly T, Levy R. Mental health and psychosocial needs of patients being treated for opioid use disorder in a primary care residency clinic. J Prim Care Community Health. 2020;11:1–8. Hooker SA, Sherman MD, Lonergan-Cullum M, Sattler A, Liese BS, Justesen K, Nissly T, Levy R. Mental health and psychosocial needs of patients being treated for opioid use disorder in a primary care residency clinic. J Prim Care Community Health. 2020;11:1–8.
14.
go back to reference Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Substance Abuse and Mental Health Services Administration; 2004. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04–3939. Substance Abuse and Mental Health Services Administration; 2004.
16.
go back to reference Kersten L, Cislo AM, Lynch M, Shea K, Trestman RL. Evaluating START NOW: a skills-based psychotherapy for inmates of correctional systems. Psychiatr Serv. 2016;67(1):37.PubMedCrossRef Kersten L, Cislo AM, Lynch M, Shea K, Trestman RL. Evaluating START NOW: a skills-based psychotherapy for inmates of correctional systems. Psychiatr Serv. 2016;67(1):37.PubMedCrossRef
17.
go back to reference Cislo AM, Trestman RL. Psychiatric hospitalization after participation in START NOW. Psychiatr Serv. 2016;67:143.PubMedCrossRef Cislo AM, Trestman RL. Psychiatric hospitalization after participation in START NOW. Psychiatr Serv. 2016;67:143.PubMedCrossRef
18.
go back to reference Frisman LK, Lin HJ, Rodis ET, Grzelak J, Aiello M. Evaluation of CT’s ASIST program: specialized services to divert higher risk defendants. Behavioral Sciences & The Law. 2017;35(5–6):550–61.CrossRef Frisman LK, Lin HJ, Rodis ET, Grzelak J, Aiello M. Evaluation of CT’s ASIST program: specialized services to divert higher risk defendants. Behavioral Sciences & The Law. 2017;35(5–6):550–61.CrossRef
19.
go back to reference Gryczynski J, Gwin Mitchell S, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abus Treat. 2014;46(3):356–61.CrossRef Gryczynski J, Gwin Mitchell S, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients’ reasons for cessation of care. J Subst Abus Treat. 2014;46(3):356–61.CrossRef
20.
go back to reference Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21(1):55–62.PubMedCrossRef Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21(1):55–62.PubMedCrossRef
21.
go back to reference Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA. Statement of the American Society of Addiction Medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254–63.PubMedCrossRef Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA. Statement of the American Society of Addiction Medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5(4):254–63.PubMedCrossRef
22.
go back to reference Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abus Treat. 2017;74:65–70.CrossRef Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abus Treat. 2017;74:65–70.CrossRef
23.
go back to reference Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17(2):116–20.PubMedCrossRef Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17(2):116–20.PubMedCrossRef
24.
go back to reference Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:171–6.PubMedPubMedCentralCrossRef Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:171–6.PubMedPubMedCentralCrossRef
25.
go back to reference Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768–74.PubMedCrossRef Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768–74.PubMedCrossRef
26.
27.
go back to reference Horowitz LM, Rosenberg SE, Baer BA, Ureño G, Villaseñor VS. Inventory of interpersonal problems: psychometric properties and clinical applications. J Consult Clin Psychol. 1988;56(6):885–92.PubMedCrossRef Horowitz LM, Rosenberg SE, Baer BA, Ureño G, Villaseñor VS. Inventory of interpersonal problems: psychometric properties and clinical applications. J Consult Clin Psychol. 1988;56(6):885–92.PubMedCrossRef
28.
go back to reference Doody O, Slevin E, Taggart L. Focus group interviews part 3: analysis. Br J Nurs. 2013;22(5):266–9.PubMedCrossRef Doody O, Slevin E, Taggart L. Focus group interviews part 3: analysis. Br J Nurs. 2013;22(5):266–9.PubMedCrossRef
29.
go back to reference Brown C, Lloyd K. Qualitative methods in psychiatric research. Adv Psychiatr Treat. 2001;7(5):350–6.CrossRef Brown C, Lloyd K. Qualitative methods in psychiatric research. Adv Psychiatr Treat. 2001;7(5):350–6.CrossRef
30.
31.
go back to reference Madden GJ, Petry NM, Badger GJ, Bickel WK. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control patients: drug and monetary rewards. Exp Clin Psychopharmacol. 1997;5(3):256–62.PubMedCrossRef Madden GJ, Petry NM, Badger GJ, Bickel WK. Impulsive and self-control choices in opioid-dependent patients and non-drug-using control patients: drug and monetary rewards. Exp Clin Psychopharmacol. 1997;5(3):256–62.PubMedCrossRef
32.
go back to reference Madden GJ, Bickel WK. Impulsivity: The behavioral and neurological science of discounting. American Psychological Association; 2010.CrossRef Madden GJ, Bickel WK. Impulsivity: The behavioral and neurological science of discounting. American Psychological Association; 2010.CrossRef
33.
go back to reference Darker C, Sweeney B, Keenan E, Whiston L, Anderson R, Barry J. Tailoring a brief intervention for illicit drug use and alcohol use in Irish methadone maintained opiate dependent patients: a qualitative process. BMC Psychiatry. 2016;16:373.PubMedPubMedCentralCrossRef Darker C, Sweeney B, Keenan E, Whiston L, Anderson R, Barry J. Tailoring a brief intervention for illicit drug use and alcohol use in Irish methadone maintained opiate dependent patients: a qualitative process. BMC Psychiatry. 2016;16:373.PubMedPubMedCentralCrossRef
34.
go back to reference Humeniuk R, Henry-Edwards S, Ali R, Poznyak V, Monteiro MG. The ASSIST-linked brief intervention for hazardous and harmful substance use: a manual for use in primary care: . Geneva: World Health Organization; 2010. Humeniuk R, Henry-Edwards S, Ali R, Poznyak V, Monteiro MG. The ASSIST-linked brief intervention for hazardous and harmful substance use: a manual for use in primary care: . Geneva: World Health Organization; 2010.
35.
go back to reference Hewell VM, Vasquez AR, Rivkin ID. Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. Substance Abuse treatment, prevention, and. Policy. 2017;12:3. Hewell VM, Vasquez AR, Rivkin ID. Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative study. Substance Abuse treatment, prevention, and. Policy. 2017;12:3.
36.
go back to reference Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abus. 2013;34(3):242–7.PubMedPubMedCentralCrossRef Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abus. 2013;34(3):242–7.PubMedPubMedCentralCrossRef
37.
go back to reference Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients' experiences and preferences. Subst Abus. 2016;37(1):70–5.PubMedCrossRef Fox AD, Masyukova M, Cunningham CO. Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients' experiences and preferences. Subst Abus. 2016;37(1):70–5.PubMedCrossRef
Metadata
Title
Systematic content analysis of patient evaluations of START NOW psychotherapy reveals practical strategies for improving the treatment of opioid use disorder
Authors
Albert Yi-Que Truong
Brian Fabian Saway
Malek H. Bouzaher
Mustafa Nawroz Rasheed
Sanaz Monjazeb
Soleille Dorothy Everest
Susan Linda Giampalmo
David Hartman
Cheryl Hartman
Anita S. Kablinger
Robert L. Trestman
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-020-03024-x

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue